{"schemaVersion":"maha-epistemic/1.0","evidencePolicyVersion":"mps/0.1","generatedAt":"2026-08-24T00:00:00.000Z","domain":{"slug":"longevity-metabolism","name":"Longevity and metabolism","description":"Autophagy, mitochondrial respiration, senescence, NAD+ metabolism, nutrient sensing, and intervention endpoints with assay-specific boundaries.","stressPoint":"A molecular marker, cell assay, or animal lifespan result cannot be silently converted into a human healthspan or treatment claim.","accent":"amber"},"lifecycle":{"status":"adversarial-pilot","foundationalTarget":30,"canonicalFactoryRecords":7,"outstandingFactoryRecords":23},"counts":{"graphRecords":30,"graphEdges":34,"publicCanonicalRecords":7,"withheldRecords":23},"records":[{"id":"urn:maha:record:longevity-metabolism-p62-sqstm1-turnover","title":"P62 sqstm1 turnover","recordKind":"comparison","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/comparisons/longevity-metabolism-p62-sqstm1-turnover","contentHash":"sha256:a1697db1c628f360e20b9f6c078a3885d8df8bbad4425a8e0f76144069f29d19","claims":[{"id":"urn:maha:claim:longevity-metabolism-p62-sqstm1-turnover","scope":"Limited to Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux. in “Guidelines for the use and interpretation of assays for monitoring autophagy”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"P62 sqstm1 turnover does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"empirical-claim","sourceIds":["source-longevity-metabolism-autophagy-guidelines"],"statement":"The cited source supports treating p62 sqstm1 turnover as a distinct comparison within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-autophagy-guidelines","url":"https://pubmed.ncbi.nlm.nih.gov/22966490/","title":"Guidelines for the use and interpretation of assays for monitoring autophagy","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Daniel J. Klionsky","et al."],"boundary":"No single marker establishes autophagy rate, organismal benefit, or a longevity outcome.","publisher":"Autophagy","establishes":"The guidelines distinguish static autophagosome measurements from dynamic flux and describe assay-specific interpretation limits.","identifiers":[{"value":"10.4161/auto.19496","scheme":"doi"}],"publishedAt":"2012-04-01","exactLocator":"Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux."}],"boundaries":["P62 sqstm1 turnover does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this p62 sqstm1 turnover record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:longevity-metabolism-autophagosome-abundance","title":"Autophagosome abundance","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/concepts/longevity-metabolism-autophagosome-abundance","contentHash":"sha256:440dcd4ab2af555ee74b03016ef572be431102611269e5de13e6e62b1079f5ea","claims":[{"id":"urn:maha:claim:longevity-metabolism-autophagosome-abundance","scope":"Limited to Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux. in “Guidelines for the use and interpretation of assays for monitoring autophagy”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"Autophagosome abundance does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"theoretical-model","sourceIds":["source-longevity-metabolism-autophagy-guidelines"],"statement":"The cited source supports treating autophagosome abundance as a distinct concept within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-autophagy-guidelines","url":"https://pubmed.ncbi.nlm.nih.gov/22966490/","title":"Guidelines for the use and interpretation of assays for monitoring autophagy","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Daniel J. Klionsky","et al."],"boundary":"No single marker establishes autophagy rate, organismal benefit, or a longevity outcome.","publisher":"Autophagy","establishes":"The guidelines distinguish static autophagosome measurements from dynamic flux and describe assay-specific interpretation limits.","identifiers":[{"value":"10.4161/auto.19496","scheme":"doi"}],"publishedAt":"2012-04-01","exactLocator":"Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux."}],"boundaries":["Autophagosome abundance does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this autophagosome abundance record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:longevity-metabolism-nad-salvage-pathway","title":"NAD+ salvage pathway","recordKind":"concept","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/concepts/longevity-metabolism-nad-salvage-pathway","contentHash":"sha256:1472ba29dfdf4a210d6c5b7d05fb679a7c370274a99ea62245ebec6ea4c65db6","claims":[{"id":"urn:maha:claim:longevity-metabolism-nad-salvage-pathway","scope":"Limited to NAD+ biosynthesis and consumption, NAD+-dependent mechanisms in ageing, therapeutic targeting, figures 1–4, and supplementary boxes. in “NAD+ metabolism and its roles in cellular processes during ageing”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"NAD+ salvage pathway does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"theoretical-model","sourceIds":["source-longevity-metabolism-nad"],"statement":"The cited source supports treating nad+ salvage pathway as a distinct concept within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-nad","url":"https://doi.org/10.1038/s41580-020-00313-x","title":"NAD+ metabolism and its roles in cellular processes during ageing","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Anthony J. Covarrubias","Rosalba Perrone","Alessia Grozio","Eric Verdin"],"boundary":"Pathway associations and model-organism interventions do not establish benefit from a human supplement or treatment.","publisher":"Nature Reviews Molecular Cell Biology","establishes":"The review maps major NAD+ synthesis and consumption pathways and their reported relationships with ageing biology.","identifiers":[{"value":"10.1038/s41580-020-00313-x","scheme":"doi"}],"publishedAt":"2020-12-22","exactLocator":"NAD+ biosynthesis and consumption, NAD+-dependent mechanisms in ageing, therapeutic targeting, figures 1–4, and supplementary boxes."}],"boundaries":["NAD+ salvage pathway does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this nad+ salvage pathway record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:longevity-metabolism-lc3-turnover-assays","title":"LC3 turnover assays","recordKind":"measurement","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/measurements/longevity-metabolism-lc3-turnover-assays","contentHash":"sha256:2a8c6710964b2740c53ac318b45d51eb423493343a901279e2866ff16412bb4a","claims":[{"id":"urn:maha:claim:longevity-metabolism-lc3-turnover-assays","scope":"Limited to Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux. in “Guidelines for the use and interpretation of assays for monitoring autophagy”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"LC3 turnover assays does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"observation","sourceIds":["source-longevity-metabolism-autophagy-guidelines"],"statement":"The cited source supports treating lc3 turnover assays as a distinct measurement within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-autophagy-guidelines","url":"https://pubmed.ncbi.nlm.nih.gov/22966490/","title":"Guidelines for the use and interpretation of assays for monitoring autophagy","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Daniel J. Klionsky","et al."],"boundary":"No single marker establishes autophagy rate, organismal benefit, or a longevity outcome.","publisher":"Autophagy","establishes":"The guidelines distinguish static autophagosome measurements from dynamic flux and describe assay-specific interpretation limits.","identifiers":[{"value":"10.4161/auto.19496","scheme":"doi"}],"publishedAt":"2012-04-01","exactLocator":"Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux."}],"boundaries":["LC3 turnover assays does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this lc3 turnover assays record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:longevity-metabolism-autophagic-flux","title":"Autophagic flux","recordKind":"mechanism","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/mechanisms/longevity-metabolism-autophagic-flux","contentHash":"sha256:da4039ab902fafe3719c466921c4950b2a726dc86f9cf16e2ad2429bcc69eaec","claims":[{"id":"urn:maha:claim:longevity-metabolism-autophagic-flux","scope":"Limited to Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux. in “Guidelines for the use and interpretation of assays for monitoring autophagy”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"Autophagic flux does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"theoretical-model","sourceIds":["source-longevity-metabolism-autophagy-guidelines"],"statement":"The cited source supports treating autophagic flux as a distinct mechanism within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-autophagy-guidelines","url":"https://pubmed.ncbi.nlm.nih.gov/22966490/","title":"Guidelines for the use and interpretation of assays for monitoring autophagy","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Daniel J. Klionsky","et al."],"boundary":"No single marker establishes autophagy rate, organismal benefit, or a longevity outcome.","publisher":"Autophagy","establishes":"The guidelines distinguish static autophagosome measurements from dynamic flux and describe assay-specific interpretation limits.","identifiers":[{"value":"10.4161/auto.19496","scheme":"doi"}],"publishedAt":"2012-04-01","exactLocator":"Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux."}],"boundaries":["Autophagic flux does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this autophagic flux record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:longevity-metabolism-lysosomal-degradation-blockade","title":"Lysosomal degradation blockade","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/methods/longevity-metabolism-lysosomal-degradation-blockade","contentHash":"sha256:e96bf30bb3509ea23e14081af9f3dcbfbbcf5ec535d4d02767543b5dabcb9905","claims":[{"id":"urn:maha:claim:longevity-metabolism-lysosomal-degradation-blockade","scope":"Limited to Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux. in “Guidelines for the use and interpretation of assays for monitoring autophagy”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"Lysosomal degradation blockade does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"theoretical-model","sourceIds":["source-longevity-metabolism-autophagy-guidelines"],"statement":"The cited source supports treating lysosomal degradation blockade as a distinct method within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-autophagy-guidelines","url":"https://pubmed.ncbi.nlm.nih.gov/22966490/","title":"Guidelines for the use and interpretation of assays for monitoring autophagy","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Daniel J. Klionsky","et al."],"boundary":"No single marker establishes autophagy rate, organismal benefit, or a longevity outcome.","publisher":"Autophagy","establishes":"The guidelines distinguish static autophagosome measurements from dynamic flux and describe assay-specific interpretation limits.","identifiers":[{"value":"10.4161/auto.19496","scheme":"doi"}],"publishedAt":"2012-04-01","exactLocator":"Assay interpretation sections for LC3, SQSTM1/p62, lysosomal inhibition, and autophagic flux."}],"boundaries":["Lysosomal degradation blockade does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this lysosomal degradation blockade record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]},{"id":"urn:maha:record:longevity-metabolism-senolytic-selectivity","title":"Senolytic selectivity","recordKind":"method","reviewState":"published-canonical","canonicalPath":"/knowledge/longevity-metabolism/methods/longevity-metabolism-senolytic-selectivity","contentHash":"sha256:80ea1c924dc05f40671f629b29a21ab73f62c676c827f03d33cd66228058914a","claims":[{"id":"urn:maha:claim:longevity-metabolism-senolytic-selectivity","scope":"Limited to Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments. in “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs”; this candidate records the concept boundary and does not pool results from uncited systems or studies.","boundary":"Senolytic selectivity does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","claimKind":"theoretical-model","sourceIds":["source-longevity-metabolism-senolytics"],"statement":"The cited source supports treating senolytic selectivity as a distinct method within the stated longevity and metabolism scope.","replication":{"asOfDate":"2026-08-24","assessment":"Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-longevity-metabolism-senolytics","url":"https://doi.org/10.1111/acel.12344","title":"The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs","rights":{"note":"The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Yi Zhu","Tamara Tchkonia","Tamar Pirtskhalava","et al."],"boundary":"Preclinical selectivity and clearance results do not establish human safety, dosing, efficacy, or lifespan extension.","publisher":"Aging Cell","establishes":"The study identifies candidate senolytic vulnerabilities and reports cell- and animal-model experiments for specified compounds.","identifiers":[{"value":"10.1111/acel.12344","scheme":"doi"}],"publishedAt":"2015-01-01","exactLocator":"Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments."}],"boundaries":["Senolytic selectivity does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.","A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record."],"prohibitedInferences":["Do not use this senolytic selectivity record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.","Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract."]}],"withheldInventory":{"recordCount":23,"edgeCount":27,"recordKinds":{"comparison":5,"concept":4,"measurement":5,"mechanism":5,"method":4},"disclosure":"aggregate-only"},"boundary":"Only active canonical records are enumerated. Draft identifiers, titles, paths, claims, sources, and gate reasons remain private until canonical release."}